A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
A Single Dose lead-in PK Followed by a Randomized, Double-blinded, Controlled, Multiple Dose Study of the Selective Progesterone Receptor Modulator Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Warsaw, Poland, 02-106
- Medical University /MTZ Clinical Research Sp.zo.o.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Had at least one leiomyomata lesion that was identifiable and measurable by transvaginal ultrasound.
- Had a regular or steady menstrual cycle lasting from 24 to 36 days.
Exclusion Criteria:
- Post-menopausal
- Subject with documented endometriosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: progenta 12.5 mg
Progenta (CDB-4124) 12.5 mg capsule
|
12.5 mg, administered as a once daily oral dose for 90 days.
Other Names:
25 mg, administered as a once daily oral dose for 90 days.
Other Names:
50 mg, administered as a once daily oral dose for 90 days.
Other Names:
|
|
EXPERIMENTAL: progenta 25 mg
Progenta (CDB-4124) 25 mg capsule
|
12.5 mg, administered as a once daily oral dose for 90 days.
Other Names:
25 mg, administered as a once daily oral dose for 90 days.
Other Names:
50 mg, administered as a once daily oral dose for 90 days.
Other Names:
|
|
EXPERIMENTAL: progenta 50 mg
Progenta (CDB-4124) 50 mg capsule
|
12.5 mg, administered as a once daily oral dose for 90 days.
Other Names:
25 mg, administered as a once daily oral dose for 90 days.
Other Names:
50 mg, administered as a once daily oral dose for 90 days.
Other Names:
|
|
ACTIVE_COMPARATOR: Lucron Depot
Lucron Depot, Leuprolide acetate for depot suspension
|
3.75 mg IM monthly
Other Names:
|
|
PLACEBO_COMPARATOR: placebo
Placebo capsule
|
Administered as a once daily oral dose for 90 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assess the safety of Progenta when administered in pre-menopausal women with symptomatic leiomyomata.
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Determine the tolerability of three doses of Progenta (12.5 mg, 25 mg, and 50 mg) as compared to placebo and Lucron Depot (leuprolide acetate for depot suspension) in pre-menopausal women with symptomatic leiomyomata.
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Connective Tissue Diseases
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Leiomyoma
- Myofibroma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Leuprolide
Other Study ID Numbers
Other Study ID Numbers
- ZN-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.